scholarly journals Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction

Addiction ◽  
2017 ◽  
Vol 112 (7) ◽  
pp. 1202-1209 ◽  
Author(s):  
Matthew J. Worley ◽  
Keith G. Heinzerling ◽  
Steven Shoptaw ◽  
Walter Ling
Keyword(s):  
Chronic Pain ◽  
Opioid Addiction ◽  
Pain Severity ◽  
Prescription Opioid

scholarly journals Longitudinal association between pain severity and subsequent opioid use in prescription opioid dependent patients with chronic pain

2016 ◽  
Vol 163 ◽  
pp. 216-221 ◽  
Author(s):  
Margaret L. Griffin ◽  
Katherine A. McDermott ◽  
R. Kathryn McHugh ◽  
Garrett M. Fitzmaurice ◽  
Robert N. Jamison ◽  
...  
Keyword(s):  
Chronic Pain ◽  
Pain Severity ◽  
Prescription Opioid ◽  
Opioid Use ◽  
Longitudinal Association

scholarly journals Pain volatility and prescription opioid addiction treatment outcomes in patients with chronic pain.

2015 ◽  
Vol 23 (6) ◽  
pp. 428-435 ◽  
Author(s):  
Matthew J. Worley ◽  
Keith G. Heinzerling ◽  
Steven Shoptaw ◽  
Walter Ling
Keyword(s):  
Chronic Pain ◽  
Treatment Outcomes ◽  
Addiction Treatment ◽  
Opioid Addiction ◽  
Prescription Opioid

scholarly journals Anhedonia in chronic pain and prescription opioid misuse

2019 ◽  
Vol 50 (12) ◽  
pp. 1977-1988 ◽  
Author(s):  
Eric L. Garland ◽  
Martin Trøstheim ◽  
Marie Eikemo ◽  
Gernot Ernst ◽  
Siri Leknes
Keyword(s):  
Chronic Pain ◽  
Large Scale ◽  
Reward Processing ◽  
Pain Severity ◽  
Prescription Opioid ◽  
Opioid Misuse ◽  
Opioid Use ◽  
Study Results ◽  
Chronic Pain Patients ◽  
Pain Patients

AbstractBackgroundBoth acute and chronic pain can disrupt reward processing. Moreover, prolonged prescription opioid use and depressed mood are common in chronic pain samples. Despite the prevalence of these risk factors for anhedonia, little is known about anhedonia in chronic pain populations.MethodsWe conducted a large-scale, systematic study of anhedonia in chronic pain, focusing on its relationship with opioid use/misuse, pain severity, and depression. Chronic pain patients across four distinct samples (N = 488) completed the Snaith–Hamilton Pleasure Scale (SHAPS), measures of opioid use, pain severity and depression, as well as the Current Opioid Misuse Measure (COMM). We used a meta-analytic approach to determine reference levels of anhedonia in healthy samples spanning a variety of countries and diverse age groups, extracting SHAPS scores from 58 published studies totaling 2664 psychiatrically healthy participants.ResultsCompared to healthy samples, chronic pain patients showed higher levels of anhedonia, with ~25% of patients scoring above the standard anhedonia cut-off. This difference was not primarily driven by depression levels, which explained less than 25% of variance in anhedonia scores. Neither opioid use duration, dose, nor pain severity alone was significantly associated with anhedonia. Yet, there was a clear effect of opioid misuse, with opioid misusers (COMM ⩾13) reporting greater anhedonia than non-misusers. Opioid misuse remained a significant predictor of anhedonia even after controlling for pain severity, depression and opioid dose.ConclusionsStudy results suggest that both chronic pain and opioid misuse contribute to anhedonia, which may, in turn, drive further pain and misuse.

Pain severity and subsequent opioid use during buprenorphine-naloxone treatment of prescription opioid-dependent patients with chronic pain

2017 ◽  
Vol 171 ◽  
pp. e215-e216 ◽  
Author(s):  
Roger Weiss ◽  
Margaret L. Griffin ◽  
Katherine McDermott ◽  
Kathryn McHugh ◽  
Sterling L. Karakula ◽  
...  
Keyword(s):  
Chronic Pain ◽  
Pain Severity ◽  
Prescription Opioid ◽  
Opioid Use ◽  
Naloxone Treatment

scholarly journals Anhedonia in chronic pain and prescription opioid misuse

2019 ◽  
Author(s):  
Eric Garland ◽  
Martin Trøstheim ◽  
Marie Eikemo ◽  
Gernot Ernst ◽  
Siri Leknes
Keyword(s):  
Chronic Pain ◽  
Large Scale ◽  
Age Groups ◽  
Reward Processing ◽  
Pain Severity ◽  
Prescription Opioid ◽  
Opioid Misuse ◽  
Opioid Use ◽  
Chronic Pain Patients ◽  
Pain Patients

BACKGROUND:Both acute and chronic pain can disrupt reward processing. Moreover, prolonged prescription opioid use and depressed mood are common in chronic pain samples. Despite the prevalence of these risk factors for anhedonia, little is known about anhedonia in chronic pain populations.METHODS:We conducted a large-scale, systematic study of anhedonia in chronic pain, focusing on its relationship with opioid use/misuse, pain severity, and depression. Chronic pain patients across four distinct samples (N = 488) completed the Snaith-Hamilton Pleasure Scale (SHAPS), measures of opioid use, pain severity and depression, as well as the Current Opioid Misuse Measure (COMM). We used a meta-analytic approach to determine reference levels of anhedonia in healthy samples spanning a variety of countries and diverse age groups, extracting SHAPS scores from 58 published studies totaling 2664 psychiatrically healthy participants.RESULTS:Compared to healthy samples, chronic pain patients showed higher levels of anhedonia, with ~25% of patients scoring above the standard anhedonia cut-off. This difference was not primarily driven by depression levels, which explained less than 25% of variance in anhedonia scores. Neither opioid use duration, dose, nor pain severity alone was significantly associated with anhedonia. Yet, there was a clear effect of opioid misuse, with opioid misusers (COMM ⩾13) reporting greater anhedonia than non-misusers. Opioid misuse remained a significant predictor of anhedonia even after controlling for pain severity, depression and opioid dose.CONCLUSIONS:Study results suggest that both chronic pain and opioid misuse contribute to anhedonia, which may, in turn, drive further pain and misuse.

scholarly journals 0368 Pain Severity as a Moderator of the Association between Prescription Opioid Use and Insomnia Symptoms among Adults with Chronic Pain

SLEEP ◽  
2018 ◽  
Vol 41 (suppl_1) ◽  
pp. A141-A141
Author(s):  
M B Miller ◽  
W S Chan ◽  
J Boissoneault ◽  
M Robinson ◽  
R Staud ◽  
...  
Keyword(s):  
Chronic Pain ◽  
Pain Severity ◽  
Prescription Opioid ◽  
Opioid Use ◽  
Prescription Opioid Use ◽  
Insomnia Symptoms

Pain severity and prescription opioid misuse among individuals with chronic pain: The moderating role of alcohol use severity

2019 ◽  
Vol 204 ◽  
pp. 107456 ◽  
Author(s):  
Daniel J. Paulus ◽  
Andrew H. Rogers ◽  
Jafar Bakhshaie ◽  
Kevin E. Vowles ◽  
Michael J. Zvolensky
Keyword(s):  
Chronic Pain ◽  
Alcohol Use ◽  
Pain Severity ◽  
Prescription Opioid ◽  
Opioid Misuse ◽  
Prescription Opioid Misuse ◽  
Moderating Role

scholarly journals Mental health and opioid addiction comorbidities among chronic pain patients

2019 ◽  
Vol 11 (1) ◽  
Author(s):  
Kevin Cevasco ◽  
Bill Saunders
Keyword(s):  
Mental Health ◽  
Chronic Pain ◽  
Substance Use ◽  
Substance Use Disorders ◽  
Opioid Addiction ◽  
Screening Tools ◽  
Prescription Opioid ◽  
Opioid Misuse ◽  
Chronic Pain Patients ◽  
Pain Patients

ObjectiveAssessing mental health and opioid addiction comorbidities among chronic pain patients using a large longitudinal clinical, operational, and laboratory data set.IntroductionThe National Institute for Drug Abuse Report, Common Comorbidities with Substance Use Disorders, states there are “many individuals who develop substance use disorders (SUD) are also diagnosed with mental disorders, and vice versa.”(1) Prescription opioids are amongst the most commonly used drugs that lead to illicit drug use.(2)Much of the data about the starting point of the prescription opioid addiction is in the patient health history and is recorded within the provider electronic health record and administrative systems.DescriptionThere are a variety of addiction and misuse risk screening tools available and selecting appropriate tools screening can be confusing for providers. Examples of common screening tools: Opioid Abuse Risk Screener (OARS), Opioid Risk Tool (ORT), Screener and Opioid Assessment for Patients with Pain (SOAPP), Current Opioid Misuse Measure (COMM), Diagnosis, Intractability, Risk, and Efficacy (DIRE). These opioid risk screening tools are interview based and vary in how they survey for psychosocial factors. The screening tools are useful, but are meant only to alert the provider to conduct further investigation.(3)Understanding how the comorbidities recorded in the patient’s clinical interactions may help improve risk assessment investigations and ongoing monitoring programs. Studying the chronic pain patients’ longitudinal clinical, operational, and laboratory records provides the basis for better study controls than those using population based on emergency department admission and mortality events.MethodsThe analysis leverages IBM's Explorys electronic health record (EHR) data, a large integrated source of real world clinical, operational and lab data across 39 large integrated delivery networks that span the continuum of care. In addition to demographic characteristics of drug abusers, we will describe common comorbidities of selected mental health diagnoses, examine coding-related issues, distinguish chronic and episodic addiction and look for regional differences due to state/local level prescribing training and provider addiction awareness.How the Moderator Intends to Engage the Audience in Discussions on the TopicPromote the event through interatction with the @ISDS twitter account and #ISDS19 hashtag.Solicit question for presenters-panelists through social media before the briefing, and meet with presenters before the event to tune the presenations to areas of interest.Conduct a demographic poll of the audience to get them engaged. Ask audience to stand to show their organization-role. e.g. state-local public health, provider, vendor. This helps the presenters adapt to the audience profile.After each panelist speaks, have the panelist ask a question to the audience about a lingering question that arose during the research. Limit the audience to ~1 minute to answer. Allow panelists to ask a few more questions if the process is working, but limit to overall event time schedule.Finish with Q&A from the audience.References1. Abuse NI on D. Part 1: The Connection Between Substance Use Disorders and Mental Illness [Internet]. [cited 2018 Sep 29]. Available from: https://www.drugabuse.gov/publications/research-reports/common-comorbidities-substance-use-disorders/part-1-connection-between-substance-use-disorders-mental-illness2. Lankenau SE, Teti M, Silva K, Bloom JJ, Harocopos A, Treese M. Initiation into prescription opioid misuse amongst young injection drug users. Int J Drug Policy. 2012 Jan 1;23(1):37–44.3. Hudspeth RS. Safe Opioid Prescribing for Adults by Nurse Practitioners: Part 1. Patient History and Assessment Standards and Techniques. J Nurse Pract. 2016 Mar;12(3):141–8. 

Sign in / Sign up

Export Citation Format

Share Document